Renzapride

DB04917InvestigationalSmall molecule

Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in... It is being developed by Alizyme of the UK.

Mechanism: Renzapride is a full serotonin 5-HT4 receptor agonist and partial serotonin 5-HT3 receptor antagonist.
Curator reviewed
Primary indication: For the treatment of constipation-predominant irritable bowel syndrome (IBS-C).Curator reviewed
Formula / weight: C₁₆H₂₂ClN₃O₂ · 323.818 g/mol (avg)
Code names: ATL-1251

Resolves to

Compound

UNII9073C0W4E9CAS112727-80-7PubChem3052778

Structure

InChIKeyYFUAYKVMQVBSNG-UHFFFAOYSA-NSMILESCOC1=C(C=CC(N)=C1Cl)C(=O)NC1CCN2CCCC1C2

Targets

Q13639HTR4P46098HTR3A

What you can answer from here — as of September 15, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

680Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Renzapride, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account